Skip to main content
    M

    Mirum Pharmaceuticals Inc (MIRM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $91.95
    +0.37 (+0.40%)

    Market Cap: $5.98B

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Mirum Pharmaceuticals Inc (MIRM) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Mirum Pharmaceuticals (MIRM) has a market cap of $5.98B and an enterprise value of $6.47B. Its share count is up 29.40% from a year earlier. It kept -134.75% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 8.16% above the market cap, as debt exceeds cash.

    Market Cap$5.98B
    Enterprise Value$6.47B
    Latest price (Nov 17, 2026)$91.95

    Key Dates

    Last Earnings DateNov 3, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 3.40% in the quarter ended Sep 30, 2026 and grew 17.11% a year over 2 years.

    Shares Outstanding65.53M
    Shares Change (YoY)+29.40%
    Shares Change (QoQ)+3.40%
    Share Count Growth (2Y CAGR)+17.11%

    Valuation Ratios

    The price to sales ratio is 9.0x. Its year-end P/S ranged from 5.8x to 25.3x from 2021 to 2025.

    P/S Ratio9.0x
    Forward P/S8.3x

    Price Statistics

    The stock is up 28.71% over 52 weeks and trades 3.96% above its 50-day average.

    Beta (1Y)1.08
    52-Week Change+28.71%
    1-Month Change+11.81%
    3-Month Change-10.06%
    6-Month Change-3.87%
    5-Year Change+435.26%
    Total Return (1Y)+28.71%
    Total Return (3Y CAGR)+41.69%
    Total Return (5Y CAGR)+42.72%
    Return vs SPY (1Y)+15.81%
    Max Drawdown (1Y)-38.36%
    Max Drawdown (3Y)-38.36%
    Sharpe Ratio (1Y)0.50
    Correlation with SPY (1Y)0.30
    50-Day Average$88.45
    200-Day Average$98.29
    52-Week Range$63.23 to $130.00
    RSI (14 Days)54.9
    Average Volume (20 Days)601.41K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.07x current liabilities.

    Current Ratio2.07x
    Quick Ratio1.98x
    Interest Coverage-79.06x

    Returns and Efficiency

    Return on invested capital is -133.57% over the last 12 months, against a 5-year average of -3.16%.

    Return on Assets (ROA)-88.04%
    Return on Invested Capital (ROIC)-133.57%
    ROE (5Y Average)-55.50%
    ROA (5Y Average)-21.62%
    ROIC (5Y Average)-3.16%
    Asset Turnover0.74x
    Inventory Turnover4.78x
    Receivables Turnover4.45x
    Cash Conversion Cycle103 days

    Scores

    MIRM has an Altman Z-Score of -0.69, in the distress zone below 1.81, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.

    Altman Z-Score-0.69
    Altman Z ZoneDistress
    Piotroski F-Score6 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $670.78M over the last 12 months is up 42.18% from the 12 months before.

    Revenue$670.78M
    Revenue Growth (YoY)+42.18%
    Gross Profit$548.19M
    Operating Income-$896.32M
    Pretax Income-$900.41M
    Net Income-$903.88M
    EBITDA-$875.16M
    Reported EPS (TTM)-$2.87

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$243.19M
    Total Debt$731.25M
    Net Debt$488.06M
    Net Debt Per Share$7.45
    Working Capital$303.55M
    Shareholder Equity-$54.19M
    Tangible Book Value-$329.83M
    Total Assets$1.03B
    Total Liabilities$1.08B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $2.59M of capital spending, operating cash flow left -$273.85M of free cash flow.

    Operating Cash Flow-$271.26M
    Capital Expenditures$2.59M
    Free Cash Flow-$273.85M
    FCF Per Share-$4.22
    Depreciation and Amortization$29.17M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -133.62%.

    Gross Margin81.72%
    Operating Margin-133.62%
    Pretax Margin-134.23%
    Net Margin-134.75%
    EBITDA Margin-130.47%
    FCF Margin-40.83%
    Gross Margin (5Y Average)83.05%

    Growth

    Revenue grew 89.13% a year over 3 years.

    Revenue Growth (3Y CAGR)+89.13%
    Book Value Per Share Growth (2Y CAGR)+8.53%

    Revenue and profit by year

    Dividends and Yields

    MIRM does not pay a dividend. Its free cash flow yield is -4.55%.

    FCF Yield-4.55%
    Buyback Yield-4.98%
    Shareholder Yield-4.98%

    Peer Position

    Against 7 similar companies, MIRM has the 4th highest P/S.

    P/S Ratio9.0x vs 8.6x median
    ROIC-133.57% vs -26.18% median
    Revenue Growth (Trailing 4 Quarters, YoY)+42.18% vs +31.82% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 29.08% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+29.08%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About MIRM

    What is MIRM's market cap?

    Mirum Pharmaceuticals has a market cap of $5.98B. Its enterprise value, which adds debt and subtracts cash, is $6.47B.

    How many shares of MIRM are outstanding?

    Mirum Pharmaceuticals has 65.53M shares outstanding. The count is up 29.40% from a year earlier.

    Does MIRM pay a dividend?

    No. Mirum Pharmaceuticals does not pay a dividend.

    How much debt does MIRM have?

    Mirum Pharmaceuticals has $731.25M of total debt and $243.19M of cash and equivalents, a net debt position of $488.06M.